Research Advisory Committee on Gulf War Veterans’ Illnesses (RAC-GWVI)
AChEi Brief: References
Acetylcholinesterase Inhibitor Brief: References
1. Fricker RD, Reardon E, Spektor DM, et al. A Review of the Scientific Literature as It Pertains to Gulf War Illnesses. Volume 12: Pesticide Use During the Gulf War: A Survey of Gulf War Veterans. Santa Monica, CA: RAND, MR-1018/12-OSD; 2000.
2. Golomb BA. Illness in Persian Gulf War veterans: Evidence for a causal role for acetylcholinesterase inhibitors (pyridostigmine bromide, pesticides, and nerve agent). Submitted.
3. Nisenbaum R, Barrett DH, Reyes M, Reeves WC. Deployment stressors and a chronic multisymptom illness among Gulf War veterans. J Nerv Ment Dis. 2000;188:259-66.
4. Unwin C, Blatchley N, Coker W, et al. Health of UK servicemen who served in the Persian Gulf war. Lancet. 1999;353:169-178.
5. Golomb BA. A Review of the Scientific Literature as it Pertains to Gulf War Illnesses, Vol 2: Pyridostigmine Bromide. Santa Monica, CA: RAND; 1999:385.
6. Cecchine G, Golomb BA, Hilborne LH, Spektor DM, Anthony CR. A Review of the Scientific Literature as it Pertains to Gulf War Illnesses, Vol 8: Pesticides. Santa Monica, CA: RAND; 2000:182.
7. Li L, Shou Y, Borowitz JL, Isom GE. Reactive oxygen species mediate pyridostigmine-induced neuronal apoptosis: involvement of muscarinic and NMDA receptors. Toxicol Appl Pharmacol. 2001;177:17-25.
8. Li L, Gunasekar PG, Borowitz JL, Isom GE. Muscarinic receptor-mediated pyridostigmine-induced neuronal apoptosis. Neurotoxicology. 2000;21:541-552.
9. Pascuzzo GJ, Akaike A, Maleque MA, et al. The nature of the interactions of pyridostigmine with the nicotinic acetylcholine receptor-ionic channel complex I. Agonist, desensitizing, and binding properties. Mol Pharmacol. 1984;25:92-101.
10. Tandon P, Padilla S, Barone S, Pope CN, Tilson HA. Fenthion produces a persistent decrease in muscarinic receptor function in the adult rat retina. Toxicol Appl Pharmacol. 1994;125:271-280.
11. Tandon P, Willig S, Pope CN, Padilla S, Tilson HA. Dose-response study of the tissue-specific effects of fenthion on receptor function in rat CNS. Toxicologist. 1994;14:257.
12. Sherby SM, Eldefrawi AT, Albuquerque EX, Eldefrawi ME. Comparison of actions of carbamate anticholinesterses on the nicotinic acetylcholine receptor. Molecular Pharmacology. 1985;27:343-348.
13. Gupta RC, Patterson GT, Dettbarn W-D. Mechanisms of toxicity and tolerance to diisopropylphosphorofluoridate at the neuromuscular junction of the rat. Toxicology and Applied Pharmacology. 1986;84:541-550.
14. Eskenazi B, Bradman A, Castorina R. Exposures of children to organophosphate pesticides and their potential adverse health effects. Environ Health Perspect. 1999;107 Suppl 3:409-19.
15. Costa LG, Schwab BW, Murphy SD. Tolerance to anticholinesterase compounds in mammals. Toxicology. 1982;25:79-97.
16. Buccafusco JJ. Chronic organophosphorus exposure and cognition. 1999 Annual Report to Congress on Gulf War Veterans' Illnesses. 2000:101.
17. Lev-Lehman E, Evron T, Broide R, et al. Synaptogenesis and myopathy under acetylcholinesterase overexpression. Journal of Molecular Neuroscience. 2000;14:93-105.
18. Robinson D, McGee R. Agonist-induced regulation of neuronal nicotinic acetylcholine receptor of PC12 cells. Molecular Pharmacology. 1985;27:409-417.
19. Sherby SM, Eldefrawi AT, Albuquerque EX, Eldefrawi ME. Comparison of actions of carbamate anticholinesterses on the nicotinic acetylcholine receptor. Molecular Pharmacology. 1985;27:343-348.
20. Shaw K-P, Aracava Y, Akaike A, Daly JW, Rickett DL, Albuquerque EX. The reversible cholinesterase inhibitor physostgmine has channelblocking and agonist efects on the acetylcholine receptor-ion channel complex. Molecular Pharmacology. 1985;28:527-238.
21. Anderson RJ, Chamberlain WL, Roesner M, Dacko C, Robertson DG. Decreased tetanic contracture of rat skeletal muscle induced by pyridostigmine. J Toxicol Environ Health. 1986;18:221-230.
22. Haley RW, Billecke S, La Du BN. Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans. Toxicol Appl Pharmacol. 1999;157:227-33.
23. La Du BN, Billecke S, Hsu C, Haley RW, Broomfield CA. Serum paraoxonase (PON1) isozymes: the quantitative analysis of isozymes affecting individual sensitivity to environmental chemicals. Drug Metab Dispos. 2001;29:566-9.
24. Mackness B, Durrington PN, Mackness MI. Low paraoxonase in Persian Gulf War Veterans self-reporting Gulf War Syndrome. Biochem Biophys Res Commun. 2000;276:729-33.
25. Cherry N, Mackness M, Durrington P, et al. Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip. Lancet. 2002;359:763-4.
26. Cecchine G, Golomb B, Hilborne LH, Spektor DM, Anthony CR. A Review of the Scientific Literature as it Pertains to Gulf War Illnesses, Vol 8: Pesticides. Washington, DC: RAND; 2000:182.
27. Cherry N, Creed F, Silman A, et al. Health and exposures of United Kingdom Gulf war veterans. Part II: The relation of health to exposure. Occup Environ Med. 2001;58:299-306.
28. Gray GC, Reed RJ, Kaiser KS, Smith TC, Gastanaga VM. Self-reported symptoms and medical conditions among 11,868 Gulf War-era veterans: the Seabee Health Study. Am J Epidemiol. 2002;155:1033-44.
29. Haley RW, Kurt TL. Self-reported exposure to neurotoxic chemical combinations in the Gulf War. A cross-sectional epidemiologic study. Jama. 1997;277:231-7.
30. Kang HK, Mahan CM, Lee KY, Magee CA, Murphy FM. Illnesses among United States veterans of the Gulf War: a population-based survey of 30,000 veterans. J Occup Environ Med. 2000;42:491-501.
31. Kang H, Mahan CM, Lee KY, et al. Evidence for a deployment-related Gulf War syndrome by factor analysis. : Arch Environ Health; 2002:58.
32. Kroenke K, Koslowe P, Roy M. Symptoms in 18,495 Persian Gulf War veterans. Latency of onset and lack of association with self-reported exposures. Journal of Occupational and Environmental Medicine. 1998;40:520-8.
33. Proctor SP, Harley R, Wolfe J, Heeren T, White RF. Health-related quality of life in Persian Gulf War Veterans. Mil Med. 2001;166:510-9.
34. Reid S, Hotopf M, Hull L, Ismail K, Unwin C, Wessely S. Multiple chemical sensitivity and chronic fatigue syndrome in British Gulf War veterans. Am J Epidemiol. 2001;153:604-9.
35. Schumm WR, Reppert EJ, Jurich AP, et al. Pyridostigmine bromide and the long-term subjective health status of a sample of female reserve component Gulf War veterans: a brief report. Psychol Rep. 2001;88:306-8.
36. Schumm WR, Reppert EJ, Jurich AP, et al. Pyridostigmine bromide and the long-term subjective health status of a sample of over 700 male Reserve Component Gulf War era veterans. Psychol Rep. 2002;90:707-21.
37. White RF, Proctor SP, Heeren T, et al. Neuropsychological function in Gulf War veterans: relationships to self-reported toxicant exposures. Am J Ind Med. 2001;40:42-54.
38. McCauley LA, Rischitelli G, Lambert WE, Lasarev M, Sticker DL, Spencer PS. Symptoms of Gulf War veterans possibly exposed to organophosphate chemical warfare agents at Khamisiyah, Iraq. Int J Occup Environ Health. 2001;7:79-89.
39. McCauley L, Lasarev M, Sticker D, Rischitelli D, Spencer P. Illness experience of Gulf War veterans possibly exposed to chemical warfare agents. Am J Prev Med. 2002;23:200.
40. Gray G, Coate B, Anderson C, et al. The postwar hospitalization experience of US veterans of the Persian Gulf War. New Engl J Med. 1996;335:1505-1513.
41. Gray GC, Smith TC, Kang HK, Knoke JD. Are Gulf War veterans suffering war-related illnesses? Federal and civilian hospitalizations examined, June 1991 to December 1994. Am J Epidemiol. 2000;151:63-71.
42. Kaiser KS. Pyridostigmine bromide intake during the Persian Gulf War is not associated with postwar handgrip strength. Mil Med. 2000;165:165-8.
43. Golomb BA. Chapter 14. Chronic Effect. In: A Review of the Scientific Literature as it Pertains to Gulf War Illnesses, Vol 2: Pyridostigmine Bromide. Santa Monica, CA: RAND; 1999:385.
44. Lotti M. Low-level exposures to organophosphorus esters and peripheral nerve function. Muscle Nerve. 2002;25:492-504.
45. Ray DE. Chronic effects of low level exposure to anticholinesterases. Toxicology Letters. 1998;95:26.
46. Glass-Marmor L, Beitner R. Effects of carbamylcholine and pyridostigmine on mitochondrial-bound hexokinase in skeletal muscle and heart. Biochem Mol Med. 1996;57:67-70.
47. Francesconi R, Hubbard R, Mager M. Effects of pyridostigmine on ability of rats to work in the heat. J Appl Physiol. 1984;56:891-5.
48. Babu SR, Buckenmeyer P, Knowlton RG, Somani SM. Effect of physostigmine on plasma lactate and pyruvate in untrained/trained rats. Pharmacol Biochem Behav. 1992;42:67-73.
49. Buckenmeyer PJ, Babu SR, Knowlton RG, Somani SM. Effect of concurrent exercise and physostigmine on lactate and pyruvate in plasma, muscle, and brain tissue of rats. Pharmacol Biochem Behav. 1994;47:779-88.
50. De Pinieux G, Chariot P, Ammi-Said M, et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. British Journal of Clinical Pharmacology. 1996;42:333-7.
51. Chariot P, Monnet I, Mouchet M, et al. Determination of the blood lactate:pyruvate ratio as a noninvasive test for the diagnosis of zidovudine myopathy. Arthritis Rheum. 1994;37:583-6.
52. Barbiroli B, Frassineti C, Martinelli P, et al. Coenzyme Q10 improves mitochondrial respiration in patients with mitochondrial cytopathies. An in vivo study on brain and skeletal muscle by phosphorous magnetic resonance spectroscopy. Cellular and Molecular Biology. 1997;43:741-9.
53. Boitier E, Degoul F, Desguerre I, et al. A case of mitochondrial encephalomyopathy associated with a muscle coenzyme Q10 deficiency. Journal of the Neurological Sciences. 1998;156:41-6.
54. Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. European Neurology. 1997;37:212-8.
55. Sobreira C, Hirano M, Shanske S, et al. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency. Neurology. 1997;48:1238-43.
56. Fosslien E. Mitochondrial medicine--molecular pathology of defective oxidative phosphorylation. Ann Clin Lab Sci. 2001;31:25-67.
57. Alleva R, Tomasetti M, Andera L, et al. Coenzyme Q blocks biochemical but not receptor-mediated apoptosis by increasing mitochondrial antioxidant protection. FEBS Lett. 2001;503:46-50.
58. Di Giovanni S, Mirabella M, Spinazzola A, et al. Coenzyme Q10 reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency. Neurology. 2001;57:515-8.
59. Fernandez-Ayala DJ, Martin SF, Barroso MP, et al. Coenzyme Q protects cells against serum withdrawal-induced apoptosis by inhibition of ceramide release and caspase-3 activation. Antioxid Redox Signal. 2000;2:263-75.
60. Kagan T, Davis C, Lin L, Zakeri Z. Coenzyme Q10 can in some circumstances block apoptosis, and this effect is mediated through mitochondria. Ann N Y Acad Sci. 1999;887:31-47.
61. Mosca L, Marcellini S, Perluigi M, et al. Modulation of apoptosis and improved redox metabolism with the use of a new antioxidant formula. Biochem Pharmacol. 2002;63:1305-14.
62. Ogasahara S, Engel AG, Frens D, Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Natl Acad Sci U S A. 1989;86:2379-82.
63. Tedeschi D, Lombardi V, Mancuso M, et al. Potential involvement of ubiquinone in myotonic dystrophy pathophysiology: new diagnostic approaches for new rationale therapeutics. Neurol Sci. 2000;21:S979-80.
64. Takusa Y, Yamaguchi S. [Myopathies with miscellaneous disorders related to mitochondrial fatty acid oxidation: defective synthesis of ketone body, long-chain fatty acid transport defect, and muscular coenzyme Q10 deficiency]. Ryoikibetsu Shokogun Shirizu. 2001:90-4.
65. Folkers K, Simonsen R. Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. Biochimica et Biophysica Acta. 1995;1271:281-6.
66. Shimomura Y, Suzuki M, Sugiyama S, Hanaki Y, Ozawa T. Protective effect of coenzyme Q10 on exercise-induced muscular injury. Biochem Biophys Res Commun. 1991;176:349-55.
67. Elble R, Giacobini E, Higgins C. Choline levels are increased in cerebrospinal fluid of Alzheimer patients. Neurobiol Aging. 1989;10:45-50.
68. Berrettini WH, Garrick NA, Nurnberger JI, Jr., et al. Intravenous physostigmine increases cerebrospinal fluid neuropeptide-Y. Biol Psychiatry. 1989;26:623-30.
69. Davis KL, Faull KF, Hollister LE, Barchas JD, Berger PA. Alterations in cerebrospinal fluid dopamine metabolites following physostigmine infusion. Psychopharmacology (Berl). 1981;72:155-60.
70. Kaye JA, May C, Atack JR, et al. Cerebrospinal fluid neurochemistry in the myoclonic subtype of Alzheimer's disease. Ann Neurol. 1988;24:647-50.
71. Jolkkonen J, Soininen H, Halonen T, et al. Somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with Parkinson's disease and its relation to dementia. J Neurol Neurosurg Psychiatry. 1986;49:1374-7.
72. Gomez S, Davous P, Rondot P, Faivre-Bauman A, Valade D, Puymirat J. Somatostatin-like immunoreactivity and acetylcholinesterase activities in cerebrospinal fluid of patients with Alzheimer disease and senile dementia of the Alzheimer type. Psychoneuroendocrinology. 1986;11:69-73.
73. Hartikainen P, Reinikainen KJ, Soininen H, Sirvio J, Soikkeli R, Riekkinen PJ. Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls. J Neural Transm Park Dis Dement Sect. 1992;4:53-68.
74. Davis KL, Hollister LE, Goodwin FK, Gordon EK. Neurotransmitter metabolites in the cerebrospinal fluid of man following physostigmine. Life Sci. 1977;21:933-6.
75. Popovic M, Popovic N, Jovanova-Nesic K, et al. Effect of physostigmine and verapamil on active avoidance in an experimental model of Alzheimer's disease. Int J Neurosci. 1997;90:87-97.
76. Peskind ER, Wingerson D, Pascualy M, et al. Oral physostigmine in Alzheimer's disease: effects on norepinephrine and vasopressin in cerebrospinal fluid and plasma. Biol Psychiatry. 1995;38:532-8.
77. degli Uberti EC, Bondanelli M, Margutti A, et al. Acute administration of human galanin in normal subjects reduces the potentiating effect of pyridostigmine-induced cholinergic enhancement on release of norepinephrine and pancreatic polypeptide. Neuroendocrinology. 1996;64:398-404.
78. Araki S, Shibasaki H. [Variations in serum amylase responding to the neostigmine test in amyotrophic lateral sclerosis]. Igaku To Seibutsugaku. 1966;73:233-9.
79. Gowen GF. A second look at the neostigmine morphine test. Am Surg. 1989;55:640-4.
80. Bell IR, Patarca R, Baldwin CM, Klimas NG, Schwartz GE, Hardin EE. Serum neopterin and somatization in women with chemical intolerance, depressives, and normals. Neuropsychobiology. 1998;38:13-8.
81. Amici S, Lanari A, Romani R, Antognelli C, Gallai V, Parnetti L. Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina. Mech Ageing Dev. 2001;122:2057-62.
82. Appleyard ME, Smith AD, Berman P, et al. Cholinesterase activities in cerebrospinal fluid of patients with senile dementia of Alzheimer type. Brain. 1987;110 ( Pt 5):1309-22.
83. Appleyard ME, McDonald B. Acetylcholinesterase and butyrylcholinesterase activities in cerebrospinal fluid from different levels of the neuraxis of patients with dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry. 1992;55:1074-8.
84. Abeyta BJ, Albrecht RM, Schermer CR. Retrospective study of neostigmine for the treatment of acute colonic pseudo-obstruction. Am Surg. 2001;67:265-8; discussion 268-9.
85. Adams SB, MacHarg MA. Neostigmine methylsulfate delays gastric emptying of particulate markers in horses. Am J Vet Res. 1985;46:2498-9.
86. Amaro R, Rogers AI. Neostigmine infusion: new standard of care for acute colonic pseudo-obstruction? Am J Gastroenterol. 2000;95:304-5.
87. Alitalo I, Hietala A. Effects of atropine, isoprenaline, neostigmine and practocol on cardiac arrhythmias induced by potassium in anesthetized dogs. Nord Vet Med. 1977;29:498-501.